Seranova Bio News Today

These 16 biotech investors are all in their first decade of working in venture capital and bringing fresh perspectives to the world of biotech.

Rogue antibodies are major culprits in severe cases of COVID-19, researchers report. These autoantibodies target and react with a person’s tissues or organs similar to ones that cause autoimmune diseases such as lupus or rheumatoid arthritis. In COVID-19 cases they can attack healthy tissue in brain, blood vessels, platelets, liver, and the gastrointestinal tract, researchers report. The more autoantibodies detected, the greater the disease severity patients experience. And the autoantibodies...

By Bill Hathaway May 19, 2021 Share this with FacebookShare this with TwitterShare this with LinkedInShare this with EmailPrint this (© stock.adobe.com) The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in severe cases of COVID-19, Yale scientists report in the journal Nature. These autoantibodies target and react with a person’s tissues or organs similar to ones that cause au...

Golden Tickets winners Bolden Therapeutics and Seranova Bio will have access to a state-of-the-art lab facilities at LabCentral with mentorship and support from Biogen CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and LabCentral today announced Bolden Therapeutics and Seranova Bio as the recipients of Biogen’s Golden Tickets, an initiative offering promising winning startups one year of lab space accompanied by continued mentorship from Biogen. LabCentral ...